Dna X Inc (SONM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,034 | -9,522 | -2,906 | -90 | 1,263 |
| Depreciation Amortization | 2,643 | 1,725 | 880 | 2,206 | 1,250 |
| Accounts receivable | 4,574 | 1,978 | 1,056 | -1,722 | -7,276 |
| Accounts payable and accrued liabilities | 517 | 625 | 540 | -1,279 | 2,130 |
| Other Working Capital | -272 | 92 | 1,450 | -8,308 | -7,396 |
| Other Operating Activity | 595 | 1,542 | -1,188 | 5,141 | 6,328 |
| Operating Cash Flow | $-3,977 | $-3,560 | $-168 | $-4,052 | $-3,701 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -206 | -69 | -30 | -36 | -24 |
| Investing Cash Flow | $-206 | $-69 | $-30 | $-36 | $-24 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -147 | -110 |
| Common Stock Issued | 3,846 | 3,832 | 53 | 419 | 419 |
| Financing Cash Flow | $3,846 | $3,832 | $53 | $272 | $309 |
| Beginning Cash Position | 9,397 | 9,397 | 9,397 | 13,213 | 13,213 |
| End Cash Position | 9,060 | 9,600 | 9,252 | 9,397 | 9,797 |
| Net Cash Flow | $-337 | $203 | $-145 | $-3,816 | $-3,416 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,977 | -3,560 | -168 | -4,052 | -3,701 |
| Capital Expenditure | -206 | -69 | -30 | -36 | -24 |
| Free Cash Flow | -4,183 | -3,629 | -198 | -4,088 | -3,725 |